Neurotrypsin (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Neurotrypsin (PRSS12, UniProt P56730), HEK293-expressed. Suitable for serine protease activity assays, agrin-cleavage studies, inhibitor profiling, and antibody validation as a positive control standard.
Expression system
HEK293
Cat. #
REC-Neurotrypsin

In stock

SKU
REC-Neurotrypsin
$498.00

Target Overview

Neurotrypsin (UniProt P56730; gene PRSS12) is a secreted, multi-domain serine protease of 875 amino acids that belongs to the trypsin-like S1 family. Its domain architecture includes a signal peptide, a proline-rich region, a kringle domain, four scavenger-receptor cysteine-rich (SRCR) domains, and a C-terminal trypsin-like catalytic domain that carries the canonical His-Asp-Ser triad. This structural organisation distinguishes it from pancreatic-type trypsins and positions it as a modular extracellular protease. This recombinant is produced in HEK293 mammalian cells, a system that supports the N-linked glycosylation patterns and disulfide bonding expected of the native, secreted form. Mammalian expression is especially relevant for a protein of this complexity, where correct folding of the SRCR and kringle modules is required for authentic activity. In the laboratory, this reagent is suited for several experimental formats. Researchers use it to measure proteolytic activity against synthetic fluorogenic substrates or against the physiological substrate agrin, a heparan sulfate proteoglycan that neurotrypsin cleaves at a defined site to release a 22 kDa C-terminal fragment. The recombinant also supports inhibitor IC₅₀ determinations, substrate identification experiments by mass spectrometry, and surface plasmon resonance or bio-layer interferometry binding studies with candidate regulatory proteins. For antibody validation, this recombinant serves as a well-defined positive-control antigen in Western blot and ELISA formats. Researchers performing immunohistochemistry or Western blot detection of endogenous neurotrypsin can pair this standard directly with the Triple Point Biologics matched antibody (SKU: RP-Neurotrypsin), enabling side-by-side confirmation of band identity and assay sensitivity. Validated reactivity to human neurotrypsin has been established; cross-reactivity to non-human primate and other mammalian orthologues is predicted based on sequence conservation.

Background

Neurotrypsin (PRSS12) is expressed predominantly in neurons of the central and peripheral nervous systems, with enriched expression in cortical projection neurons, hippocampal pyramidal cells, and motor neurons. Its secretion into the synaptic cleft and extracellular matrix positions it to regulate the local proteolytic environment at sites of synaptic contact. The primary physiological substrate identified to date is agrin: neurotrypsin cleaves the heparan sulfate proteoglycan at two defined sites, generating a 90 kDa and a 22 kDa C-terminal agrin fragment. The 22 kDa fragment is detectable in cerebrospinal fluid and plasma and has been used as a biomarker proxy for neurotrypsin activity in human cohort studies. The biological role of neurotrypsin has been characterised principally in the context of synaptic plasticity. Activity-dependent release of neurotrypsin, followed by agrin cleavage and dendritic filopodium induction, has been documented in published studies, supporting the interpretation that the PRSS12/agrin axis contributes to structural remodelling of synaptic contacts associated with learning and memory. Genetic studies have further associated PRSS12 variants with non-syndromic autosomal recessive intellectual disability, making the protease a research target for understanding the molecular basis of cognitive function. Beyond the CNS, PRSS12 and its agrin-cleavage product have been investigated in the context of skeletal muscle biology. Pratt et al. (2023, Geroscience) reported associations between genetic variants in AGRN and PRSS12 and measures of muscle mass, grip strength, and circulating C-terminal agrin fragment concentration in human cohorts, identifying the neurotrypsin–agrin axis as a research target in age-related sarcopenia models. Neurotrypsin has also been studied in the context of tumour biology; transcriptomic and proteomic datasets have placed PRSS12 expression in several cancer gene signatures, though the functional significance in those contexts remains under active investigation. For researchers characterising the PRSS12/agrin axis, this recombinant provides a defined, mammalian-glycosylated enzyme source for activity measurements, inhibitor profiling, and substrate mapping. Because endogenous neurotrypsin is expressed at relatively low levels and is difficult to purify in active form from tissue, the HEK293-expressed recombinant fills a practical gap for in-vitro biochemical studies. Researchers requiring matched immunodetection reagents can pair this standard with the Triple Point Biologics RP-Neurotrypsin antibody, which has been validated for Western blot against human neurotrypsin with predicted cross-reactivity to non-human primate orthologues.

Applications

  • Serine protease activity assay using synthetic fluorogenic substrates (e.g., Boc-Phe-Ser-Arg-AMC or equivalent trypsin-site reporters)
  • Agrin cleavage assay: proteolytic release of 22 kDa C-terminal agrin fragment monitored by SDS-PAGE or Western blot
  • Inhibitor IC50 determination in fluorescence-based kinetic format against defined substrate
  • Antibody validation positive control: confirmation of band identity and molecular weight in Western blot with matched RP-Neurotrypsin antibody
  • ELISA capture or detection standard for quantification of neurotrypsin in conditioned medium or biological fluid
  • Substrate identification by mass spectrometry: incubation with candidate extracellular matrix proteins followed by LC-MS/MS peptide mapping
  • Binding interaction studies (SPR or bio-layer interferometry) with candidate regulatory proteins, inhibitors, or agrin fragments
  • Recombinant enzyme reference standard for C-terminal agrin fragment biomarker assay development

References

  1. Pratt J et al. Genes encoding agrin (AGRN) and neurotrypsin (PRSS12) are associated with muscle mass, strength and plasma C-terminal agrin fragment concentration. Geroscience. 2023. doi:10.1007/s11357-022-00721-1. PMID: 36609795
  2. Deng Y et al. GalNAc-T13 maintains neurite architecture and memory retention via O-GalNAc glycosylation of seizure protein 6. Proc Natl Acad Sci U S A. 2026. doi:10.1073/pnas.2508476123. PMID: 41790942
  3. Aragó N et al. Local co-expression of GLP1R and INS in human cortical interneurons. Front Endocrinol (Lausanne). 2026. doi:10.3389/fendo.2026.1788432. PMID: 41970992
  4. Wang L et al. Three regulatory elements upstream of LMO4 are strongly associated with intermittent fertilization intensity in Chicken. Poult Sci. 2025. doi:10.1016/j.psj.2025.104769. PMID: 39919562
  5. Li S et al. A novel fatty acid metabolism-related signature identifies MUC4 as a novel therapy target for esophageal squamous cell carcinoma. Sci Rep. 2024. doi:10.1038/s41598-024-62917-z. PMID: 38816411

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight band should I expect for recombinant Neurotrypsin on SDS-PAGE or Western blot?

The unprocessed human Neurotrypsin polypeptide has a predicted molecular weight of ~99 kDa based on its 875-amino-acid sequence (UniProt P56730). Because this recombinant is produced in HEK293 cells with native-like N-linked glycosylation, the apparent molecular weight on reducing SDS-PAGE typically runs between 110–130 kDa — noticeably higher than the sequence-predicted mass. When running a Western blot positive control alongside our matched anti-Neurotrypsin rabbit polyclonal (RP-Neurotrypsin), expect the band in this 110–130 kDa range rather than at the theoretical 99 kDa.

Does recombinant Neurotrypsin undergo autocatalytic or protease-mediated processing, and which form does TPB supply?

Full-length Neurotrypsin is expressed as a single-chain zymogen-like precursor. Physiologically, the C-terminal trypsin-like domain can be released by limited proteolysis, generating an ~80 kDa fragment retaining the SRCR domains and an ~36 kDa catalytic fragment. TPB's REC-Neurotrypsin is supplied as the full-length, largely intact 875-aa form produced in HEK293 cells. If your assay requires the isolated catalytic domain or a specific truncation, you should plan an in-vitro processing step or request the relevant fragment construct. Activity of the full-length form toward synthetic substrates is confirmed prior to release.

What chromogenic or fluorogenic substrate should I use to measure recombinant Neurotrypsin serine protease activity?

Neurotrypsin cleaves after basic residues (Arg/Lys), consistent with its trypsin-like S1 specificity. For activity assays, fluorogenic substrates such as Boc-Phe-Ser-Arg-AMC or tosyl-Gly-Pro-Arg-AMC (t-GPR-AMC) work well as starting points. Chromogenic substrates like Tos-Gly-Pro-Arg-pNA can also be used for plate-reader formats. Run reactions in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Tween-20 at 37°C. Include a soybean trypsin inhibitor (SBTI) or PMSF control to confirm serine-protease-dependent signal and rule out contaminating trypsin activity.

What buffer and assay conditions are optimal for Neurotrypsin recombinant protein proteolytic activity experiments?

The storage buffer for REC-Neurotrypsin is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For activity assays, dilute the protein into a reaction buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Tween-20 (to minimize surface adsorption), and incubate at 37°C. Glycerol from the storage buffer is typically diluted to ≤1% in the final reaction volume, which does not meaningfully affect activity. Avoid DTT concentrations above 1 mM, as excess reducing agent can disrupt the disulfide bonds critical for correct folding of the SRCR and kringle domains.

What starting concentration of recombinant Neurotrypsin should I use in a proteolytic activity or substrate cleavage assay?

For fluorogenic substrate assays (e.g., Boc-Phe-Ser-Arg-AMC at 50–200 µM), a reasonable starting enzyme concentration is 50–200 nM recombinant Neurotrypsin. Titrate down from there to identify linear-range conditions for your specific substrate and instrument. For cell-based or extracellular matrix degradation experiments, 10–100 nM added exogenously to conditioned medium or a reconstituted matrix is a reported working range in the literature. Always include a no-enzyme blank and a serine protease inhibitor (1 mM PMSF or 10 µM leupeptin) control to confirm signal specificity.

Can I use REC-Neurotrypsin as a positive control for Western blot with the RP-Neurotrypsin rabbit polyclonal antibody?

Yes — that is one of the primary intended uses for this pairing. Load 20–50 ng of REC-Neurotrypsin per lane on a standard 8–10% SDS-PAGE gel; this quantity reliably produces a clean band at ~110–130 kDa with our matched RP-Neurotrypsin antibody. The recombinant and antibody are produced from the same source construct and validated together in-house, so cross-reactivity is confirmed rather than predicted. This makes the pairing useful both as a daily positive control and for establishing antibody working dilutions when you are setting up RP-Neurotrypsin for the first time on your samples.

How much recombinant Neurotrypsin should I load for Western blot positive control alongside cell lysate samples?

Start with 25–50 ng of REC-Neurotrypsin per lane, run adjacent to your cell lysate lanes on the same gel. At this loading, RP-Neurotrypsin (SKU: RP-Neurotrypsin) at a 1:1000–1:2000 primary antibody dilution typically yields a strong, clean band at ~110–130 kDa within a standard 1-hour ECL exposure. If your lysate lanes require longer exposure times due to low endogenous expression, you may reduce the recombinant control load to 10–15 ng to avoid signal saturation on the same blot. Purity of >95% by SDS-PAGE means the dominant band is neurotrypsin, reducing ambiguity.

How should I store and handle recombinant Neurotrypsin to maintain activity, and what is the shelf life?

REC-Neurotrypsin is shipped on dry ice and should be stored at −20°C immediately upon receipt in single-use aliquots. Repeated freeze-thaw cycles measurably reduce enzymatic activity due to the structural complexity of the multi-domain architecture (kringle, four SRCR domains, catalytic domain), so aliquot before freezing if your stock arrives as a single vial. On ice, the protein is stable for 4–6 hours during an experiment. Under proper −20°C storage, activity is maintained for at least 12 months from the date of manufacture. Do not store at 4°C long-term; activity loss is significant within days at that temperature.

Validation imagery coming soon

Western blot validation figures for REC-Neurotrypsin will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →